Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
19.50
-0.45 (-2.26%)
At close: Dec 5, 2025, 4:00 PM EST
19.55
+0.05 (0.26%)
After-hours: Dec 5, 2025, 5:20 PM EST
Zai Lab Employees
Zai Lab had 1,869 employees as of December 31, 2024. The number of employees decreased by 306 or -14.07% compared to the previous year.
Employees
1,869
Change (1Y)
-306
Growth (1Y)
-14.07%
Revenue / Employee
$236,292
Profits / Employee
-$110,654
Market Cap
2.17B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZLAB News
- 24 days ago - Zai Lab Limited: Declining Despite Making Progress - I See Opportunity (Reiterate Buy) - Seeking Alpha
- 4 weeks ago - Zai Lab Limited (ZLAB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates - Business Wire
- 5 weeks ago - Zai Lab Announces Participation in Investor Conferences in November and December 2025 - Business Wire
- 6 weeks ago - Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Suzhou and Outlines Next Steps in Clinical Development Transcript - Seeking Alpha
- 6 weeks ago - Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study - Business Wire
- 7 weeks ago - Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 - Business Wire
- 7 weeks ago - Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - Business Wire